Arch Pathol Lab Med:主动监测或可改善前列腺癌患者生存治疗

2014-09-09 伊文 生物谷

在美国,前列腺癌是引发男性死亡的第二大主要病因,而主动监测则为前列腺癌患者提供了一种避免癌症治疗副作用的方法;近日,来自西达斯西奈医学中心(Cedars-Sinai Medical Center)的研究者表示,进行必要的主动监测对于改善患者的生存治疗以及疗法的作用非常关键,相关研究刊登于国际杂志Archives of Pathology&nbsp

在美国,前列腺癌是引发男性死亡的第二大主要病因,而主动监测则为前列腺癌患者提供了一种避免癌症治疗副作用的方法;近日,来自西达斯西奈医学中心(Cedars-Sinai Medical Center)的研究者表示,进行必要的主动监测对于改善患者的生存治疗以及疗法的作用非常关键,相关研究刊登于国际杂志Archives of Pathology & Laboratory Medicine上。

在主动监测的条件下,患者就会进行有规律的前列腺特异性抗原(PSA)的检测及活组织检查,Mahul Amin博士表示,主动监测对于低风险前列腺癌男性来讲也是一项非常重要的管理策略,进行主动监测的关键就在于获取病理学参数,这对于确定那些高风险的患者来讲也很有必要。

文章中,研究者表示,病理学参数可以帮助筛选出那些利用主动监测获得成功的患者,其主要包括:取样、组织穿刺、病例组织处理、对针刺活组织进行肿瘤内容物检查以及进行Gleason评分等等。研究者指出,对于活组织检查所得到的结果必须要能够重复出来,这对于进行准确的病理学报告很关键。

最后研究者表示,PSA筛选和不断改变PSA的检测环节或许在一定程度上会引发前列腺癌被过度诊断以及过度治疗,因此进行主动监测就显得越发重要了。

原始出处:

Amin MB1, Lin DW, Gore JL, Srigley JR, Samaratunga H, Egevad L, Rubin M, Nacey J, Carter HB, Klotz L, Sandler H, Zietman AL, Holden S, Montironi R, Humphrey PA, Evans AJ, Epstein JI, Delahunt B, McKenney JK, Berney D, Wheeler TM, Chinnaiyan AM, True L, Knudsen B, Hammond E.The Critical Role of the Pathologist in Determining Eligibility for Active Surveillance as a Management Option in Patients With Prostate Cancer: Consensus Statement With Recommendations Supported by the College of American Pathologists, International Society of Urological Pathology, Association of Directors of Anatomic and Surgical Pathology, the New Zealand Society of Pathologists and the Prostate Cancer Foundation.Arch Pathol Lab Med. 2014 Aug 5. [pdf free]

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1786146, encodeId=b1d21e8614694, content=<a href='/topic/show?id=569f13e9045' target=_blank style='color:#2F92EE;'>#Pathol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13790, encryptionId=569f13e9045, topicName=Pathol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Mon Jan 12 19:15:00 CST 2015, time=2015-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932508, encodeId=a52b1932508a0, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Sat Jun 13 15:15:00 CST 2015, time=2015-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506575, encodeId=b5b715065e55f, content=<a href='/topic/show?id=d4b923144d0' target=_blank style='color:#2F92EE;'>#主动监测#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23144, encryptionId=d4b923144d0, topicName=主动监测)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d419776525, createdName=linne323, createdTime=Thu Sep 11 02:15:00 CST 2014, time=2014-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606280, encodeId=5cb9160628068, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Sep 11 02:15:00 CST 2014, time=2014-09-11, status=1, ipAttribution=)]
    2015-01-12 yb6560
  2. [GetPortalCommentsPageByObjectIdResponse(id=1786146, encodeId=b1d21e8614694, content=<a href='/topic/show?id=569f13e9045' target=_blank style='color:#2F92EE;'>#Pathol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13790, encryptionId=569f13e9045, topicName=Pathol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Mon Jan 12 19:15:00 CST 2015, time=2015-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932508, encodeId=a52b1932508a0, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Sat Jun 13 15:15:00 CST 2015, time=2015-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506575, encodeId=b5b715065e55f, content=<a href='/topic/show?id=d4b923144d0' target=_blank style='color:#2F92EE;'>#主动监测#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23144, encryptionId=d4b923144d0, topicName=主动监测)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d419776525, createdName=linne323, createdTime=Thu Sep 11 02:15:00 CST 2014, time=2014-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606280, encodeId=5cb9160628068, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Sep 11 02:15:00 CST 2014, time=2014-09-11, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1786146, encodeId=b1d21e8614694, content=<a href='/topic/show?id=569f13e9045' target=_blank style='color:#2F92EE;'>#Pathol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13790, encryptionId=569f13e9045, topicName=Pathol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Mon Jan 12 19:15:00 CST 2015, time=2015-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932508, encodeId=a52b1932508a0, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Sat Jun 13 15:15:00 CST 2015, time=2015-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506575, encodeId=b5b715065e55f, content=<a href='/topic/show?id=d4b923144d0' target=_blank style='color:#2F92EE;'>#主动监测#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23144, encryptionId=d4b923144d0, topicName=主动监测)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d419776525, createdName=linne323, createdTime=Thu Sep 11 02:15:00 CST 2014, time=2014-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606280, encodeId=5cb9160628068, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Sep 11 02:15:00 CST 2014, time=2014-09-11, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1786146, encodeId=b1d21e8614694, content=<a href='/topic/show?id=569f13e9045' target=_blank style='color:#2F92EE;'>#Pathol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13790, encryptionId=569f13e9045, topicName=Pathol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Mon Jan 12 19:15:00 CST 2015, time=2015-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932508, encodeId=a52b1932508a0, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Sat Jun 13 15:15:00 CST 2015, time=2015-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506575, encodeId=b5b715065e55f, content=<a href='/topic/show?id=d4b923144d0' target=_blank style='color:#2F92EE;'>#主动监测#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23144, encryptionId=d4b923144d0, topicName=主动监测)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d419776525, createdName=linne323, createdTime=Thu Sep 11 02:15:00 CST 2014, time=2014-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606280, encodeId=5cb9160628068, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Sep 11 02:15:00 CST 2014, time=2014-09-11, status=1, ipAttribution=)]